- Home
- TAYD vs NGEN Comparison
TAYD vs NGEN Comparison
Compare TAYD & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TAYD | NGEN |
|---|---|---|
| Founded | 1955 | 2017 |
| Country | United States | Canada |
| Employees | N/A | 9 |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.7M | 197.5M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | TAYD | NGEN |
|---|---|---|
| Price | $57.03 | $2.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $70.00 | $18.00 |
| AVG Volume (30 Days) | 39.7K | ★ 844.8K |
| Earning Date | 03-31-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.24 | N/A |
| EPS | ★ 2.87 | N/A |
| Revenue | ★ $46,292,725.00 | N/A |
| Revenue This Year | $0.25 | N/A |
| Revenue Next Year | $19.78 | N/A |
| P/E Ratio | $19.88 | ★ N/A |
| Revenue Growth | ★ 3.84 | N/A |
| 52 Week Low | $40.50 | $1.70 |
| 52 Week High | $90.37 | $5.93 |
Technical Indicators
Market Signals| Indicator | TAYD | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 52.60 | 45.40 |
| Support Level | $56.80 | $1.70 |
| Resistance Level | $59.99 | $2.35 |
| Average True Range (ATR) | 2.74 | 0.17 |
| MACD | 0.16 | 0.08 |
| Stochastic Oscillator | 43.47 | 60.87 |
Price Performance
Historical ComparisonAbout TAYD Taylor Devices Inc.
Taylor Devices Inc is involved in the design, development, manufacture, and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The company's product line includes Seismic dampers, Fluidicshoks, Crane and industrial buffers, Self-adjusting shock absorbers, Liquid die springs, and Vibration Dampers. Its products are generally used to absorb, control, or mitigate the motion of masses caused by earthquakes or explosions. The company markets its products to various industries such as industrial, steel mills, buildings, bridges, aerospace, defense, and automotive industries.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.